Gilead Sciences (NASDAQ:GILD) introduced its second-quarter 2025 earnings and revised annual outlook after the market closed on Thursday.
The HIV drug maker reported adjusted earnings of $2.01 per share, beating the consensus of $1.94. Gross sales reached $7.08 billion, beating the consensus of $6.94 billion.
Whole second quarter 2025 product gross sales elevated 2%, and excluding Veklury, the gross sales have been up 4% to $6.9 billion, primarily as a consequence of greater HIV, Livdelzi (seladelpar), and Trodelvy (sacituzumab govitecan-hziy) gross sales, partially offset by decrease persistent hepatitis C virus (HCV) gross sales.
Additionally Learn: Gilead’s Newly Accepted HIV Prevention Drug Poised To Add Billions To Future Gross sales
Biktarvy gross sales elevated 9% to $3.5 billion, primarily pushed by greater demand.
Descovy gross sales elevated 35% to $653 million, primarily pushed by greater common realized value and demand.
The Liver Illness portfolio gross sales decreased 4% to $795 million, primarily pushed by decrease HCV gross sales, partially offset by elevated demand for Livdelzi, Hepcludex (bulevirtide), and persistent hepatitis B virus (HBV) merchandise.
Veklury gross sales decreased 44% to $121 million.
Cell Remedy product gross sales decreased 7% to $485 million, reflecting ongoing aggressive headwinds.
Trodelvy gross sales elevated 14% to $364 million, primarily pushed by greater demand and stock dynamics.
Product gross margin was 78.7% within the second quarter of 2025 in comparison with 77.7% a yr in the past.
Non-GAAP product gross margin was 86.9% within the second quarter 2025 in comparison with 86.0% in the identical interval in 2024. The will increase have been primarily pushed by product combine.
Gilead licensed a brand new $6.0 billion inventory repurchase program, with no fastened expiration, which is able to begin upon the completion of the beforehand authorized program.
Gilead Sciences raised fiscal 2025 adjusted earnings steering from $7.70-$8.10 per share to $7.95-$8.25 in comparison with the consensus of $7.96.
The corporate additionally elevated its 2025 gross sales steering from $28.2 billion-$28.6 billion to $28.3 billion-$28.7 billion in comparison with the consensus of $28.65 billion.
Gilead sees Veklury gross sales of $1 billion, down from prior steering of $1.4 billion.
Individually, Arcus Biosciences Inc (NASDAQ:RCUS) and Gilead agreed to not pursue a Part 3 examine for etrumadenant (adenosine A2a/A2b receptor antagonist). In June, Gilead returned its license to etrumadenant to Arcus.
In its second quarter earnings launch, Arcus stated it engaged with the FDA in March concerning outcomes from the ARC-9 examine evaluating etrumadenant in third-line metastatic colorectal most cancers.
